Cambridge / London (dpa-AFX) – Astrazeneca . pharmaceutical company
AstraZeneca recently announced the creation of its Vaccines & Antibody Therapeutics division. In November, the British-Swedish company also announced that it no longer wanted to sell its coronavirus vaccine at cost. It was said that many profit-making agreements have been signed for 2022. This is how competitors achieve Pfizer
AXC0298 2021-12-03 / 19:10
Copyright dpa-AFX Wirtschaftsnachrichten GmbH. All rights reserved. No redistribution, republication or permanent storage is permitted without the prior express consent of dpa-AFX.
“Total coffee aficionado. Travel buff. Music ninja. Bacon nerd. Beeraholic.”